Crohn's Disease Market Is Predicted To Exhibit Remarkable Growth From (2024-2034), Analyzes Delveinsight
Crohns
Source: menafn.com
📰 Falk Pharma News
Falk Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Falk Pharma. Real-time updates on events, politics, business and more.
Head to Head Review: Takeda Pharmaceutical (NYSE:TAK) vs. Nurix Therapeutics (NASDAQ:NRIX)
Takeda Pharmaceutical (NYSE:TAK – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Volatility and Risk Takeda Pharmaceutical has a beta […]
Source: wkrb13.com
Comparing Cosmo Pharmaceuticals (OTC:CMOPF) and AbbVie (NYSE:ABBV)
Cosmo Pharmaceuticals (OTC:CMOPF – Get Free Report) and AbbVie (NYSE:ABBV – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk. Insider and Institutional Ownership 70.2% of AbbVie shares are […]
United States North Chicago Venclexta Venclyxto Uceris Cortiment Tentarix Biotherapeutics Mavyret Maviret
Source: modernreaders.com
Primary Sclerosing Cholangitis Market to Grow at a Tremendous CAGR of 17.2% During the Study Period (2019-2032)
/PRNewswire/ -- DelveInsights Primary Sclerosing Cholangitis Market Insights report includes a comprehensive understanding of current treatment practices,...
Source: prnewswire.com
Long-term risk of arrhythmias in patients with inflammatory bowel disease: A population-based, sibling-controlled cohort study
In a population-based, sibling-controlled cohort study Jiangwei Sun and colleagues explore the long-term risk of arrhythmias in patients with inflammatory bowel disease.
Source: plos.org
Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma
Cosmo Pharmaceuticals N.V. / Key word(s): AgreementTermination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma 04.09.2023 / 05:45 GMT/BSTDublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the termination by mutual agreement of the license with Dr....
France General Hazel Winchester Falk Pharma Multi Matrix Technology Cosmo Pharmaceuticalsnv Key Cosmo Pharmaceuticals
Source: pharmiweb.com
Global Dermatology Partnering 2016-2023: Deal Trends, Players and Financials
/PRNewswire/ -- The "Global Dermatology Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.coms offering....
Nordrhein Westfalen United Kingdom United States Case Western Reserve University Alpha Pharma Karo Pharma
Source: prnewswire.com
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
Etrasimod was effective and well tolerated as an induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. Etrasimod is a treatment option with a unique combination of attributes that might address the persistent unmet needs of patients with ulcerative colitis.
Source: thelancet.com
Long-term risk of inflammatory bowel disease after endoscopic biopsy with normal mucosa: A population-based, sibling-controlled cohort study in Sweden
Jiangwei Sun and colleagues investigate the long-term risk of inflammatory bowel disease after endoscopic biopsy with normal mucosa in a Swedish cohort.
Source: plos.org
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
News reports, trends, analysis and Daily Updates on Business, New Emerging Technology, Startups, Funding, and Innovation in India and across the World
Source: indianweb2.com